# OnCo record braf-v600-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/braf-v600-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "braf-v600-melanoma" ;
  schema:name "BRAF V600-mutant melanoma"@en ;
  schema:alternateName "BRAF-mutant melanoma"@en, "BRAF V600E melanoma"@en, "BRAF V600K melanoma"@en, "BRAF-positive melanoma"@en ;
  schema:description "BRAF V600-mutant melanoma has a single faulty switch that drives it to grow, and two pills, a BRAF inhibitor with a MEK inhibitor, can shut that switch off and shrink the cancer within weeks. Immunotherapy is usually given first because its effect lasts longer, and the pills are kept for later or given for a year after surgery to prevent relapse."@en ;
  schema:url <https://onco.cc/cancers/braf-v600-melanoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BRAF_(gene)> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)60898-4>, <https://ascopubs.org/doi/10.1200/JCO.22.01763>, <https://en.wikipedia.org/wiki/BRAF_(gene)> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/secondary-brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/mek/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/melanoma-signalling/> ;
  onco:terms <https://onco.cc/terms/braf-v600-mutation/> ;
  onco:trials <https://onco.cc/trials/combi-d/>, <https://onco.cc/trials/cobrim/>, <https://onco.cc/trials/columbus/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/trials/dreamseq/> ;
  onco:people <https://onco.cc/people/keith-flaherty/>, <https://onco.cc/people/georgina-long/>, <https://onco.cc/people/paolo-ascierto/> ;
  onco:pipeline <https://onco.cc/trials/seacraft-2/>, <https://onco.cc/drugs/naporafenib/>, <https://onco.cc/trials/nct07449754/>, <https://onco.cc/trials/nct04417621/>, <https://onco.cc/trials/nct04657991/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-melanoma/> ;
  onco:standardOfCare <https://onco.cc/trials/dreamseq/>, <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/trials/combi-d/>, <https://onco.cc/trials/cobrim/>, <https://onco.cc/trials/columbus/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/trials/checkmate-204/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/> .